Long-Term Opioid and Gabapentinoid Related Harms in CKD.
4 affiliations
- 1Division of Population Health and Genomics, School of Medicine, University of Dundee, Dundee, UK.
- 2School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, UK.
- 3Division of Population and Behavioral Sciences, School of Medicine, University of St Andrews, St Andrews, UK.
- 4School of Public Health and Emergency Management, School of Medicine, Southern University of Science and Technology, Shenzhen, China.
Abstract
Introduction
Chronic pain affects over half of the patients with chronic kidney disease (CKD). This study aimed to evaluate the association between new long-term opioids or gabapentinoids and the risk of death, hospitalization, and hip fractures in adults with CKD.Methods
This is a retrospective, time-updated, population-based cohort study from the East of Scotland (N = 953,542) using linked routinely collected data. The study population included adults with biochemically confirmed CKD (estimated glomerular filtration rate [eGFR] <60 ml/min per 1.73 m²) without kidney failure from 2010 to 2023. The primary exposures were new, long-term cumulative opioids or gabapentinoids. Discrete time logistic regression modelling with generalized estimating equations and adjustment for relevant covariates and treatment allocation bias was used to determine the association between chronic analgesic use and all-cause mortality.Results
A total of 30,674 adults with CKD entered the study. Of them, 21,440 patients without prevalent analgesic use were included in the primary and secondary analyses (median follow-up 4.3 years). Among 2399 patients with at least 1 continuous 90-day episode of opioid prescriptions during follow-up, 1159 died. The risk of death increased as continuous 90-day opioid stretches (reference 0) increased from 1 (absolute risk of death: 0.4% [0.3-0.4]; odds ratio [OR]: 1.09 [1.06-1.12], P < 0.001) to 6 (absolute risk of death: 0.6% [0.5-0.7]; OR: 1.68 [1.41-2.00], P < 0.001). Long-term gabapentinoids were potentially associated with a modest increase in death amongst males (OR: 1.04 [1.00-1.08], P = 0.050), but not females (OR: 1.02 [0.99-1.05], P = 0.201).Conclusion
Long-term opioid use is associated with increased mortality and hospitalization in adults with CKD independent of demographics, comorbidities, and treatment allocation bias. These findings support prioritization of safer pain management strategies in people with CKD.
Related
- Predictors of opioid use at long-term follow-up following radiation therapy for head and neck cancer
- Patterns of complementary and alternative medicine and health care utilization among long-term opioid users with chronic non-cancer pain: a repeated cross-sectional study.
- Daily personalized music listening versus audiobook listening for chronic non-cancer pain in patients on long-term opioid therapy: a randomized controlled trial
- Short- and long-term outcome evaluation of a university-based opioid overdose education and naloxone distribution (OEND) program
- A systematic review and meta-analysis of comprehensive community initiatives on tobacco use and related harms
BibTeX
@article{grant2026longterm,
title = {{Long-Term Opioid and Gabapentinoid Related Harms in CKD.}},
author = {Christopher H Grant and Shona Livingstone and Huan Wang and Karen N Barnett and Patrick B Mark and Lesley A Colvin and Samira Bell},
journal = {Kidney international reports},
year = {2026},
month = sep,
doi = {10.1016/j.ekir.2026.107085},
url = {https://europepmc.org/article/MED/42910008},
note = {CC BY},
}
RIS
TY - JOUR
TI - Long-Term Opioid and Gabapentinoid Related Harms in CKD.
AU - Christopher H Grant
AU - Shona Livingstone
AU - Huan Wang
AU - Karen N Barnett
AU - Patrick B Mark
AU - Lesley A Colvin
AU - Samira Bell
PY - 2026
DA - 2026/09/17
JO - Kidney international reports
DO - 10.1016/j.ekir.2026.107085
UR - https://europepmc.org/article/MED/42910008
AB - Introduction Chronic pain affects over half of the patients with chronic kidney disease (CKD). This study aimed to evaluate the association between new long-term opioids or gabapentinoids and the risk of death, hospitalization, and hip fractures in adults with CKD.Methods This is a retrospective, time-updated, population-based cohort study from the East of Scotland (N = 953,542) using linked routinely collected data. The study population included adults with biochemically confirmed CKD (estimated glomerular filtration rate [eGFR] <60 ml/min per 1.73 m²) without kidney failure from 2010 to 2023. The primary exposures were new, long-term cumulative opioids or gabapentinoids. Discrete time logistic regression modelling with generalized estimating equations and adjustment for relevant covariates and treatment allocation bias was used to determine the association between chronic analgesic use and all-cause mortality.Results A total of 30,674 adults with CKD entered the study. Of them, 21,440 patients without prevalent analgesic use were included in the primary and secondary analyses (median follow-up 4.3 years). Among 2399 patients with at least 1 continuous 90-day episode of opioid prescriptions during follow-up, 1159 died. The risk of death increased as continuous 90-day opioid stretches (reference 0) increased from 1 (absolute risk of death: 0.4% [0.3-0.4]; odds ratio [OR]: 1.09 [1.06-1.12], P < 0.001) to 6 (absolute risk of death: 0.6% [0.5-0.7]; OR: 1.68 [1.41-2.00], P < 0.001). Long-term gabapentinoids were potentially associated with a modest increase in death amongst males (OR: 1.04 [1.00-1.08], P = 0.050), but not females (OR: 1.02 [0.99-1.05], P = 0.201).Conclusion Long-term opioid use is associated with increased mortality and hospitalization in adults with CKD independent of demographics, comorbidities, and treatment allocation bias. These findings support prioritization of safer pain management strategies in people with CKD.
SN - 2468-0249
ER -